将mTICI2b级再灌注改善至mTICI2c/3级再灌注:一项评估技术可行性、安全性和临床疗效的回顾性观察研究
该回顾性观察研究分析了246例大脑中动脉闭塞成功再灌注病例,评估将mTICI2b改善至mTICI2c/3的技术可行性、安全性及临床疗效。结果显示mTICI2c与mTICI3患者结局相似,mTICI2b患者神经功能改善率和良好功能结局率均较低;28例mTICI2b改善至mTICI2c/3无并发症,直接与二次改善的mTICI2c/3结局无差异。
要点
- mTICI2c与mTICI3再灌注患者临床结局相似,均优于mTICI2b。
- 将mTICI2b改善至mTICI2c/3在部分病例中技术可行且安全,28例无并发症。
- 直接与二次改善获得的mTICI2c/3患者结局无显著差异。
核心结论
- 将mTICI2b再灌注改善至mTICI2c/3有时技术可行且安全,临床获益与直接获得mTICI2c/3相当;若被证实,对已获mTICI2b者采取更积极治疗可能合理,但需恰当患者选择。
研究设计与样本
- 回顾性观察研究,纳入246例大脑中动脉闭塞成功再灌注且每次操作间均有血管造影可用的患者,采用包含TICI2c的改良TICI评分评估最终及单次操作间再灌注成功情况。
诊断标准与关键数值
- 采用包含TICI2c的改良TICI评分;最终TICI2c/3再灌注二分为「直接」(最终操作前再灌注≤mTICI2a)或「二次改善」(曾达到mTICI2b)。
临床应用与阅片要点
- 与mTICI2c/3患者相比,mTICI2b患者神经功能改善率较低(33.3% vs 61.2%,p<0.001),良好功能结局率较低(28.7% vs 46.5%,p=0.008)。
- 28例mTICI2b再灌注改善至mTICI2c/3无并发症。
- 「直接」与「二次改善」的mTICI2c/3患者结局无差异(p>0.5)。
局限性
- 原文为回顾性分析。
- 结论指出「若被证实」,提示需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Recent studies suggested that modified Thrombolysis in Cerebral Infarction grade (mTICI) 3 reperfusions are associated with superior outcome to mTICI2b reperfusions, questioning if neurointerventionalists should generally strive to achieve mTICI3.
METHODS: Retrospective analysis of successfully reperfused MCA occlusions (n=246) with available angiography runs between every manoeuvre was performed. Final reperfusion success and those between all single manoeuvres were evaluated applying the modified version of the TICI score (including TICI2c). Final TICI2c/3 reperfusions were dichotomized as 'direct' (reperfusion before final manoeuvre ≤mTICI2a) or 'secondary improved' (mTICI2b was achieved).
RESULTS: Patients with mTICI2c reperfusion had similar outcome to patients with mTICI3 rather than mTICI2b reperfusions. Compared with mTICI2c/3-patients, mTICI2b-patients had lower rates of neurological improvement (33.3% vs. 61.2%, p<0.001) and good functional outcome (28.7% vs. 46.5%, p=0.008). In 28 patients, mTICI2b reperfusion was improved to mTICI2c/3 without complications. Outcome of patients with 'direct' or 'secondary improved' mTICI2c/3 did not differ (p>0.5).
CONCLUSION: Improving mTICI2b reperfusions to mTICI2c/3 reperfusions is sometimes technically feasible and safe, and associated with clinical benefit comparable to 'direct' mTICI2c/3 reperfusions. If confirmed, a more aggressive treatment approach in cases of already achieved mTICI2b may be justified, although proper patient selection is needed.
KEY POINTS: • Patients with mTICI2c or 3 reperfusions have a comparable clinical course. • mTICI2c/3 are associated with a larger therapeutic benefit than are mTICI2b reperfusions. • Improving reperfusion from mTICI2b to mTICI2c/3 is sometimes feasible and reasonably safe. • Outcome of patients with 'secondary improved' and 'direct' mTICI2c/3 is not different.
引用
- Kaesmacher J, Maegerlein C, Zibold F, et al. Improving mTICI2b reperfusion to mTICI2c/3 reperfusions: A retrospective observational study assessing technical feasibility, safety and clinical efficacy. Eur Radiol. 2017. PMID: 28752216. doi:10.1007/s00330-017-4928-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。